Evidence map›Paper›PMID 37903506›Full record

ArticleACS chemical neuroscience2023

Patient Brain Organoids Identify a Link between the 16p11.2 Copy Number Variant and the

Milos Kostic, Joseph J Raymond, Christophe A C Freyre, Beata Henry, Tayfun Tumkaya, Jivan Khlghatyan, Jill Dvornik, Jingyao Li, Jack S Hsiao, Seon Hye Cheon and 5 more

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. The pleiotropic spectrum of proximal 16p11.2 CNVs.American journal of human genetics · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Milos KosticNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Joseph J RaymondNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Christophe A C FreyreNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.ORCID 0000-0001-6775-4665
Beata HenryNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Tayfun TumkayaNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Jivan KhlghatyanNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Jill DvornikNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Jingyao LiNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Jack S HsiaoNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Seon Hye CheonNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Jonathan ChungChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Yishan SunNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Ricardo E DolmetschNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Kathleen A WorringerNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.
Robert J IhryNeuroscience, Novartis Institutes for BioMedical Research, Cambridge 02139, Massachusetts, United States.ORCID 0000-0003-4519-3136

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copy number variants (CNVs) that delete or duplicate 30 genes within the 16p11.2 genomic region give rise to a range of neurodevelopmental phenotypes with high penetrance in humans. Despite the identification of this small region, the mechanisms by which 16p11.2 CNVs lead to disease are unclear. Relevant models, such as human cortical organoids (hCOs), are needed to understand the human-specific mechanisms of neurodevelopmental disease. We generated hCOs from 17 patients and controls, profiling 167,958 cells with single-cell RNA-sequencing analysis, which revealed neuronal-specific differential expression of genes outside the 16p11.2 region that are related to cell-cell adhesion, neuronal projection growth, and neurodevelopmental disorders. Furthermore, 16p11.2 deletion syndrome organoids exhibited reduced mRNA and protein levels of RBFOX1, a gene that can also harbor CNVs linked to neurodevelopmental phenotypes. We found that the genes previously shown to be regulated by RBFOX1 are also perturbed in organoids from patients with the 16p11.2 deletion syndrome and thus identified a novel link between independent CNVs associated with neuronal development and autism. Overall, this work suggests convergent signaling, which indicates the possibility of a common therapeutic mechanism across multiple rare neuronal diseases.

Indexed as

Chromosome DeletionDNA Copy Number VariationsAutistic DisorderBrainChromosome DisordersChromosomes, Human, Pair 16HumansIntellectual DisabilityOrganoidsPhenotypeRNA Splicing FactorsRBFOX1 protein, humanRNA Splicing Factors16p11.2autismbrain organoidsCNVRBFOX1scRNA-seq

Identifiers

PMID37903506
PMCPMC10655044
OpenAlexW4388015677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.